抑制线粒体谷氨酰胺酶活性可逆转非小细胞肺癌性厄洛替尼耐药.pdfVIP

Oncotarget,Vol.7,No.1

Inhibitionofmitochondrialglutaminaseactivityreverses

acquirederlotinibresistanceinnon-smallcelllungcancer

111111

CaifengXie,JiangboJin,XujieBao,Wei-HuaZhan,Tian-YuHan,MingxiGan,

11

ChengfuZhang,JianbinWang

1

InstituteofTranslationalMedicine,NanchangUniversity,Nanchang,Jiangxi,P.R.China

Correspondenceto:JianbinWaen-gm,ail:jianbinwang1@g

Keywords:non-smallcelllungcancer,erlotinib,glutaminaseinhibitor-968,epidermalgrowthfactorreceptor

Received:April12,2015Accepted:October29,2015Published:November13,2015

Theepidermalgrowthfactorreceptor(EGFR)tyrosinekinaseinhibitor(TKI)

erlotinibhasbeenapprovedbasedontheclinicalbenefitinnon-smallcelllungcancer

(NSCLC)patientsoverthepastdecade.Unfortunately,cancercellsbecomeresistant

tothisagentviavariousmechanisms,andthislimitstheimprovementinpatient

outcomes.Thus,itisurgenttodevelopnovelagentstoovercomeerlotinibresistance.

Here,weproposeanovelstrategytoovercomeacquirederlotinibresistanceinNSCLC

byinhibitingglutaminaseactivity.Compound968,aninhibitorofthegluta